Pacira BioSciences
Develops non-opioid pain and musculoskeletal treatments built on a liposome drug-delivery platform.
$25.76
After-hours close0.00 (0.00%)
At close$25.76(−0.27%)
Something off on this page? Send us feedback.
Breakdown13F · Form 4
Institutions 116.73%Insiders 3.80%
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 39.34M · Float 37.68M · 95.8% free float
Institutions13F, as of Jun 30, 2026
256 holders · 45.91M shares · 38 new positions · 121 increased · 84 reduced · 26 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 6.71M | 17.05% | −29.5K | Aug 7, 2026 |
| Doma Perpetual Capital Management LLC | 2.78M | 7.06% | 0 | Aug 12, 2026 |
| Vanguard Portfolio Management LLC | 2.41M | 6.12% | −95.0K | Aug 13, 2026 |
| Dimensional Fund Advisors LP | 2.10M | 5.35% | +42.6K | Aug 11, 2026 |
| State Street Corp | 2.06M | 5.24% | +140.4K | Aug 7, 2026 |
| D. E. Shaw & Co., Inc. | 1.95M | 4.96% | −32.4K | Aug 14, 2026 |
| Renaissance Technologies LLC | 1.73M | 4.41% | −91.7K | Aug 13, 2026 |
| Vanguard Capital Management LLC | 1.69M | 4.30% | −92.5K | Aug 13, 2026 |
Beneficial owners13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 15.20% | 7.02M | 13G | Apr 28, 2025 ↗ |
| Pedro Escuderoincl. DOMA Perpetual Partners GP LLC, DOMA Perpetual LO Equity Master Fund LP +5 more | 7.30% | 2.94M | 13D | Mar 12, 2026 ↗ |
| Vanguard Portfolio Management | 6.38% | 2.59M | 13G | May 1, 2026 ↗ |
| State Street Corporation | 5.20% | 2.06M | 13G | Aug 7, 2026 ↗ |
| Vanguard Capital Management | 5.15% | 2.09M | 13G | May 1, 2026 ↗ |
| Dimensional Fund Advisors LP | 5.10% | 2.06M | 13G | Apr 9, 2026 ↗ |
InsidersForm 4
| Insider | Role | Shares | % outstanding | Filed |
|---|---|---|---|---|
| Frank D. Lee | director, officer: Chief Executive Officer | 660.8K | 1.68% | Feb 13, 2026 |
| Jonathan Slonin | officer: Chief Medical Officer | 216.4K | 0.55% | Aug 18, 2026 |
| Kristen Williams | officer: Chief Administrative Officer | 167.1K | 0.42% | Jun 5, 2026 |
| Shawn Cross | officer: Chief Financial Officer | 105.3K | 0.27% | Apr 24, 2026 |
| Brendan Teehan | officer: Chief Commercial Officer | 100.9K | 0.26% | Feb 13, 2026 |
| Lauren Riker | officer: Senior Vice President, Finance | 62.3K | 0.16% | Jun 12, 2026 |
| Mark A. Kronenfeld | director | 31.1K | 0.08% | Mar 19, 2026 |
| Laura Brege | director | 30.1K | 0.08% | Jun 12, 2026 |
| Mark Froimson | director | 26.5K | 0.07% | Jun 12, 2026 |
| Christopher Christie | director | 23.1K | 0.06% | Jun 12, 2026 |
5 ten-percent owners hold 10.82M shares by Form 4, outside the officers-and-directors figure above · 23 people have not refiled in the last 18 months (2.76M shares), so they are not in the figure above
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 17, 2026 | Jonathan Sloninofficer: Chief Medical Officer | Sale | 3,040 | $23.23 | 216,384 |
| Jun 11, 2026 | Lauren Rikerofficer: Senior Vice President, Finance | Sale | 6,115 | $23.50 | 62,284 |
| Jun 4, 2026 | Kristen Williamsofficer: Chief Administrative Officer | Sale | 10,259 | $22.27 | 167,062 |
| Apr 23, 2026 | Shawn Crossofficer: Chief Financial Officer | Sale | 12,941 | $25.16 | 105,341 |
| Apr 20, 2026 | Shawn Crossofficer: Chief Financial Officer | Sale | 7,714 | $25.14 | 105,341 |
| Apr 22, 2026 | Shawn Crossofficer: Chief Financial Officer | Sale | 1,500 | $25.01 | 105,341 |
| Mar 17, 2026 | Mark Froimsondirector | Sale | 500 | $21.81 | 20,136 |
| Mar 17, 2026 | Jonathan Sloninofficer: Chief Medical Officer | Sale | 3,261 | $22.82 | 223,640 |
| Feb 2, 2026 | Kristen Williamsofficer: Chief Administrative Officer | Sale | 13,137 | $20.53 | 131,303 |
| Feb 2, 2026 | Lauren Rikerofficer: Senior Vice President, Finance | Sale | 4,000 | $20.81 | 52,313 |
CongressHouse and Senate disclosures
Not reported.